Status:
COMPLETED
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
HPV Infection
HPV Vaccination
Eligibility:
All Genders
16-25 years
Phase:
PHASE4
Brief Summary
The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infectio...
Detailed Description
Background: Genital Human Papilloma Virus (HPV) infections occur rapidly after sexual debut, and immunosuppressed individuals are at greater risk for incident and persistent infection. HPV vaccine con...
Eligibility Criteria
Inclusion
- HIV-infected
- enrolled previously and received received three doses of quadrivalent HPV- vaccine in 2014
Exclusion
- Decline re-enrollment
- unable to provide informed consent
- minor without parent or guardian consent
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT05435209
Start Date
May 25 2022
End Date
October 31 2023
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Phrd-Ccr-Kemri
Thika, Kiambu County, Kenya